Oncimmune's proprietary platform is underpinned by rapid biomarker discovery and a comprehensive immunogenic protein library of over 8,000 antigenic proteins. Oncimmune has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making. Oncimmune's patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.
Healthcare/Medical Diagnostics & Research
Europe, United Kingdom
Diagnostics, Immuno-Oncology, Oncology
184 Shepherd’s Bush Road
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
European Biotech Investor Day 2019
New York City,
August 1, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by